frank_armstrong_chairman

Uni spin out gets new chariman, CFO, COO

pharmafile | May 27, 2016 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |   

Caldan Therapeutics is a spin-out company from the Universities of Glasgow and Southern Denmark which is looking at developing novel therapies targeting free fatty acid receptors for the treatment of metabolic disease, such as Type-2 diabetes.

The company has announced a string of new appointments, including chief financial officer, chief operating officer, VP in drug discovery and non-executive chariman. Chief among its investors is Epidarex Capital, an early-stage life sciences venture capital fund who count Eli Lilly as one of numerous partners in the fund.

Dr Philip Boyd has been named chief financial officer. He has previously held roles at Ipsen Bioinnovation (formerly Syntaxin), Oxford Biodynamics and Tiziana Pharmaceuticals.

Advertisement

The new chief operating officer is Dr Gerry Thomas. He is a medicinal chemist with over 22 years in the pharmaceutical and biotech industry. He previously held roles at Boots, BASF and OSI Prosidion.

Other new members of the team include Dr Stephen Connolly as VP, drug discovery and Dr Franck M Armstrong as anon-executive chairman. The latter has held senior roles at Merck Serono, Bayer and Zeneca.

Related Content

No items found
The Gateway to Local Adoption Series

Latest content